In August CTS begins source plasma testing as a new line of business to one of the largest plasma fractionators in the industry.
CTS embraces a company-wide operational excellence initiative designed to change the culture to enha...
In 2016, CTS tested more source plasma samples (4.9 million) than blood donor samples (4.5 million).
Transitioned all 5 CTS labs from an investigational new drug (IND) to a licensed pooled Babesia test...
By the end of 2017, CTS has secured three source plasma partners and continues to seek additional pa...
In January, CTS is incorporated as a non-profit organization owned by Vitalant and OneBlood (formerl...
As a component of the CTS Business Continuity Plan, today all 6 labs began using the same laboratory...